Morgan Stanley Maintains Equal-Weight on CR Bard

Morgan Stanley reiterates its Equal-weight on CR Bard (NYSE: BCR) to reflect the company's expensive chase to achieve growth.

Following company guidance, Morgan Stanley says, "Guidance was inline with MS previewed expectations excluding Lutonix dilution. Revenue guidance may prove 100 bps aggressive as it centers on flat organic growth y/y after 2 quarters of deceleration. Lutonix risk/reward nearly balanced."

BCR closed at $87.78 per share on Tuesday.